Company Encyclopedia
View More
name
Enzolytics, Inc.
ENZC.US
Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus.
1.908 T
ENZC.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Enzolytics Inc. Reports Continued Zero Sales and Increased Net Loss of $92,239 for Q1 2025, EPS Unchanged at $(0.00)

    Enzolytics Inc. reported zero sales and a net loss of $92,239 for Q1 2025, with EPS unchanged at $(0.00). The loss improved from $172,757 in Q1 2024, while expenses decreased to $82,983 from $172,721. Cash and cash equivalents fell to $0 from $14,682 at the end of 2024. The company continues to operate without sales, focusing on expense management, and did not provide future guidance.

    Reuters·
    US
    ENZC
    -33.33%
    Reuters·
    US
    ENZC
    -33.33%

    Enzolytics Inc. Releases 2024 Annual Report

    Enzolytics Inc. has released its 2024 Annual Report, revealing total current assets of $200,005,177, down from $360,014,682 the previous year. The report highlights a significant business combination with Sagaliam Acquisition Corp., leading to the sale of its subsidiaries, Virogenetics, Inc. and Biogenysis, Inc., for $450 million. Following this, Biogenysis, Inc. was returned to Enzolytics, while Virogenetics, Inc. was exchanged for 20 million shares of Sagaliam Acquisition Corp.

    Reuters·
    US
    ENZC
    -33.33%
    Reuters·
    US
    ENZC
    -33.33%

    Enzolytics Inc. Reports No Sales for 2024, Net Loss Narrows to $394,188, EPS Remains at $0.00

    Enzolytics Inc. reported no sales for 2024, a drop from $84,951 in 2023. The net loss narrowed to $394,188 from $2,688,821 the previous year, with EPS remaining at $0.00. Total current assets decreased to $200 million from $360 million, mainly due to reduced investment in SAGA shares. Financial statements were prepared by Camelot Financial, including a balance sheet and income statement.

    Reuters·
    US
    ENZC
    -33.33%
    Reuters·
    US
    ENZC
    -33.33%